Optogenetic gene therapy provides a mutation-independent strategy for vision restoration in advanced inherited retinal diseases (IRDs) characterized by irreversible photoreceptor loss. MCO-010 (Nanoscope Therapeutics) employs an adeno-associated virus serotype 2 (AAV2)-vectored multi-characteristic opsin designed to transduce ON bipolar cells within the inner nuclear layer, restoring photosensitivity following a single intravitreal administration. RhyGaze utilizes a similar bipolar-cell targeting approach but incorporates proprietary red-shifted opsins delivered via an AAV2/8 hybrid capsid to enhance low-light performance and channel kinetics. This review compares preclinical mechanisms, molecular design, and clinical development pathways of both therapies through late 2025. MCO-010 has demonstrated sustained improvements in best-corrected visual acuity (≥0.3 LogMAR) and significant quality-of-life gains in Phase 2b/3 trials, with durability reported up to five years. Regulatory advancement includes a rolling Biologics License Application submission. In contrast, RhyGaze remains in early clinical development, with interim Phase 1 data indicating promising visual acuity improvements but limited long-term safety and efficacy validation. While both platforms aim to restore functional vision in end-stage retinal degeneration, differences in spectral sensitivity, vector design, and clinical maturity distinguish their translational potential. Continued long-term evaluation will be essential to determine durability, safety, and real-world performance
Keywords: Optogenetic gene therapy; MCO-010; RhyGaze; inherited retinal diseases; mutation-independent vision restoration; ON bipolar cells; retinal degeneration; AAV vectors.
How to cite this article: Karaarslan C, Comparative Analysis of MCO-010 and RhyGaze in Mutation Independent Vision Restoration. Int J Drug Deliv Technol. 2026;16(1): 210-214. DOI: 10.25258/ijddt.16.1.22